Goldman Sachs
Revvity Enters Into $1.5B Credit Facility
The firm said that the unsecured $1.5 billion revolving credit facility through 2030 replaces another $1.5 billion credit facility through 2026.
Adaptive Biotechnologies to Keep MRD and Immune Medicine Businesses Following Strategic Review
The Seattle-based firm is restructuring to increase each unit's independence by allocating them resources and separating their reporting.
Adaptive Bio Initiates Strategic Review, Considers Separation of MRD, Immune Medicine Businesses
Premium
While reporting its Q3 earnings results, Adaptive said it hired Goldman Sachs to perform "a review of strategic alternatives" for its MRD and immune medicine businesses.
Myriad Genetics to Raise $110M in Public Stock Offering
The Salt Lake City-based genetic testing and precision medicine company is offering 6,470,588 shares of its common stock at a public offering price of $17 per share.
Pacific Biosciences to Raise $175M in Public Stock Offering
The company is selling 17.5 million shares of its common stock at a price of $10 per share in the offering, which is expected to close Jan. 27.